Tris Pharma, Inc.

Jan 29, 2019

Tris Pharma, Inc. Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen

Jan 17, 2019

Tris Pharma to Present Three Posters Covering Data on Dyanavel® XR and Tris' LiquiXR® Technology at the 2019 APSARD Annual Meeting

Dec 05, 2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Nov 12, 2018

Tris Pharma Presents Clinical Data for DYANAVEL® XR (amphetamine) at the 2018 Neuroscience Education Institute (NEI) Congress

Oct 10, 2018

Tris Pharma Announces Hiring of Chief Commercial Officer

Sep 25, 2018

Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals

Aug 27, 2018

Tris Pharma Announces Hiring of New Vice President of Quality & Compliance